Figure 1
Figure 2
The meta-analysis of the the vaspin rs2236242 polymorphism in the MetS patients (n = 469) and the control group (n = 459) from Iran, Egypt and Poland_
| Genotypes | MetS Patients n (%) | Control Group n (%) | χ2(df=2) | ρ Value |
|---|---|---|---|---|
| TT | 210 (44.78) | 149 (32.46) | ||
| TA | 215 (45.84) | 240 (52.59) | 24.20 | <0.0001 |
| AA | 34 (7.25) | 70 (15.25) | ||
| Alleles | χ2(df=l) | ρ Value | ||
| Τ | 635 (67.70) | 538 (58.61) | 33.21 | <0.0001 |
| A | 283 (30.17) | 380 (41.39) |
Associations between the vaspin rs2236242 polymorphism a risk of MetS and its components [OR (95% CI)]_ I: unadjusted model; II: model adjusted for gender, age, smoking, walking and interactions between the vaspin rs2236242 polymorphism and walking in relation to MetS and its components; III: model adjusted for gender, age, smoking, BMI, walking and interactions between the vaspin rs2236242 gene polymorphism and walking in relation to MetS or its components_
| Components of MetS | AA (TTref.) | ρ Value | TA (TT ret) | p Value | TA+AA (TTref.) | ρ Value | AA (TT+TAref.) | p Value | |
|---|---|---|---|---|---|---|---|---|---|
| MetS | I | 0.54 (0.22-1.35) | 0.187 | 0.15 (0.65-2.02) | 0.638 | 0.99 (0.58-1.71) | 0.979 | 0.50(0.21-1.18) | 0.115 |
| II | 1.24(0.31-4.97) | 0.759 | 2.54 (1.07-60.5)a | 0.035 | 2.14 (0.96-4.77)· | 0.064 | 0.75 (0.20-2.83) | 0.674 | |
| III | 0.91 (0.19-4.36 | 0.911 | 2.96 (1.07-7.40)a | 0.020 | 2.37 (1.01-5.57)· | 0.047 | 0.60 (0.14-2.48) | 0.480 | |
| Abdominal obesity | I | 0.80 (0.32-2.04) | 0.647 | 1.13 (0.60-2.12) | 0.699 | 1.05 (0.58-1.91) | 0.861 | 0.75 (0.32-1.79) | 0.521 |
| II | 1.61 (0.28-9.36) | 0.593 | 0.91 (0.34-2.43) | 0.846 | 1.02 (0.40-2.62) | 0.961 | 1.41 (0.26-7.72) | 0.695 | |
| III | 1.21 (0.11-12.77) | 0.874 | 1.84 (0.45-7.57) | 0.398 | 1.59 (0.43-5.09) | 0.483 | 0.50 (0.07-3.78) | 0.506 | |
| Elevated BP | I | 0.71 (0.26-1.94) | 0.503 | 0.89 (0.45-1.78) | 0.744 | 0.85 (0.44-1.64) | 0.627 | 0.75 (0.30-1.92) | 0.554 |
| II | 0.60 (0.20-1.77) | 0.356 | 1.88 (0.64-5.52)b | 0.251 | 2.38 (0.84-6.77)» | 0.103 | 0.61 (0.23-1.64) | 0.332 | |
| III | 0.44 (0.13-1.49) | 0.187 | 1.86 (0.63-7.04)b | 0.265 | 2.42 (0.83-7.04)» | 0.104 | 0.62 (0.22-1.72) | 0.360 | |
| Increased glucose | I | 0.80(0.31-2.06) | 0.648 | 1.14 (0.63-2.05) | 0.663 | 1.07 (0.61-1.87) | 0.823 | 0.75 (0.41-1.80) | 0.517 |
| concentration | II | 1.02 (0.24-4.33) | 0.978 | 0.41 (0.60-3.30) | 0.424 | 1.30 (0.58-2.91) | 0.527 | 0.76 (0.19-2.97) | 0.696 |
| III | 0.78 (0.17-3.58) | 0.748 | 1.46 (0.61-3.47) | 0.395 | 1.29 (0.56 (2.96) | 0.544 | 0.65 (0.16-2.62) | 0.546 | |
| Decreased HDL | I | 0.56 (0.19-1.64) | 0.290 | 1.06 (0.57-1.96) | 0.852 | 0.95 (0.52-1.172) | 0.861 | 0.54 (0.19-1.50) | 0.238 |
| concentration | II | 1.44(0.31-4.78) | 0.642 | 1.84 (0.74-4.60) | 0.189 | 1.72 (0.72-4.11) | 0.219 | 1.10 (0.26-4.67) | 0.899 |
| III | 1.26 (0.25-6.21) | 0.778 | 1.91 (0.76-4.79) | 0.170 | 1.72 (0.71-4.16) | 0.224 | 0.99 (0.22-4.36) | 0.990 | |
| Increased TG | I | 0.60 (0.22-1.66) | 0.324 | 1.42 (0.79-2.56) | 0.245 | 1.22 (0.69-2.15) | 0.493 | 0.49 (0.19-1.28) | 0.148 |
| concentration | II | 2.34 (0.57-9.64)c | 0.237 | 2.02 (0.854.78) | 0.110 | 2.09 (0.92-4.75) | 0.076 | 1.66 (0.44-6.24)c | 0.456 |
| III | 1.92 (0.42-8.09)c | 0.399 | 2.12 (0.88-5.11) | 0.095 | 2.15 (0.93-5.00) | 0.075 | 1.49 (0.37-5.97)c | 0.569 |
Genolype and allele distribution of the vaspin rs2236242 polymorphism in the control group and MetS patients_
| Genotypes | Total n(%) | Control Group n (%) | MetS Patients n (%) | χ2(df=2) | p Value |
|---|---|---|---|---|---|
| TT | 86 (39.45) | 43 (39.10) | 43 (39.81) | ||
| TA | 106 (48.62) | 50 (45.45) | 56 (51.86) | 2.783 | 0250 |
| AA | 26 (11.93) | 17(15.45) | 9 (8.33) | ||
| Alleles | χ2 (df = 1) | ρ Value | |||
| Τ | 278 (63.76) | 126 (61.82) | 142 (65.74) | 0.730 | 0.394 |
| A | 158 (36.24) | 84 (38.18) | 74 (34.26) |